Back to top
more

INmune Bio (INMB)

(Delayed Data from NSDQ)

$11.84 USD

11.84
441,538

+0.07 (0.59%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $11.84 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for INMB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for INmune Bio, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 36 52 75 22 7
Receivables 2 8 6 2 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 2 4 2 0 0
Total Current Assets 40 65 83 24 8
Net Property & Equipment 0 0 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 17 17 17 17 17
Deposits & Other Assets 0 0 0 0 0
Total Assets 57 82 100 41 24
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8 5 4 2 1
Current Portion Long-Term Debt 10 5 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 0 0 0
Total Current Liabilities 18 11 4 2 1
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 10 14 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 1 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 20 22 20 2 1
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 159 152 144 72 45
Retained Earnings -121 -91 -64 -33 -21
Other Equity -1 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 37 60 80 39 24
Total Liabilities & Shareholder's Equity 57 82 100 41 24
Total Common Equity 37 60 80 39 24
Shares Outstanding 18.00 17.90 17.80 13.40 10.70
Book Value Per Share 2.07 3.36 4.51 2.89 2.21

Fiscal Year End for INmune Bio, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 36 42 48 51
Receivables NA 2 2 2 2
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 2 2 3 4
Total Current Assets NA 40 46 53 57
Net Property & Equipment NA 0 0 0 0
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 17 17 17 17
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 57 63 70 74
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 8 4 2 2
Current Portion Long-Term Debt NA 10 10 10 8
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 1 1 1
Total Current Liabilities NA 18 14 13 10
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 2 5 7
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 20 19 19 19
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 159 157 155 154
Retained Earnings NA -121 -113 -104 -98
Other Equity NA -1 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 37 44 51 55
Total Liabilities & Shareholder's Equity NA 57 63 70 74
Total Common Equity 0 37 44 51 55
Shares Outstanding 18.00 18.00 18.00 17.90 17.90
Book Value Per Share 0.00 2.07 2.44 2.83 3.09